T2DM: KOL Insight Contents

T2DM: KOL Insight

Report Overview > Pipeline Programmes > Marketed Therapies > KOLs Interviewed > Methodology > Research Objectives > Ongoing Benefits >

2 Report Overview

T2DM: KOL Insight

Instead of asking KOLs generic questions about the strengths and weaknesses of current and pipeline therapies, Therapy Trends analysts focus the research on the key battlegrounds for market share, i.e. the emphasis is on segments of the market which are likely to have the greatest impact going forward.

We are able to spend more time asking very in-depth questions about specific products ensuring more valuable insights are generated.

3 Pipeline Therapies

T2DM: KOL Insight Efficacy

At-a-glance view of key data on late-stage Tolerability pipeline therapies. For most of the programmes Safety listed below, the report includes tables covering: Key Trials to Watch

GLP-1 agonists Basal franchise (oral & once weekly NN1218/FIAsp (; Novo Nordisk) injectable formulations; Novo Nordisk) ITCA 650 (; Intarcia Therapeutics) Basal insulin/GLP-1 agonist LixiLan (/; Sanofi) SGLT-2 inhibitor (PF04971729; Pfizer/Merck & Co.)

4 Marketed Therapies

T2DM: KOL Insight Commercial Profile At-a-glance view of key data on approved and off-label therapies. For each therapy listed Efficacy below, the report includes tables covering: Tolerability GLP-1 agonists Safety Lyxumia/Adlynx (lixisenatide; Sanofi) Tresiba (; Novo Nordisk) Tanzeum/ Eperzan (; GSK) Toujeo/Optisulin (insulin glargine; Sanofi) Trulicity (delaglutide; Eli Lilly) Abasaglar/Basaglar (insulin glargine biosimilar; Eli Lilly/Boehringer Ingelheim) DPP-4 inhibitors Onglyza (; AstraZeneca) Fixed Dose Combinations (FDCs) Nesina/Vipidia (; Takeda) Synjardy (/ [SGLT-2i/]; Tradjenta/Trajenta (; Boehringer Boehringer Ingelheim) Ingelheim) Qtern/SaxaDapa (saxagliptin/ [SGLT- Zafatek (trelagliptin; Takeda/Furiex) 2i/DPP-4i]; AstraZeneca) Glyxambi (empagliflozin/linagliptin [SGLT-2i /DPP-4i]; SGLT-2 inhibitor Boehringer Ingelheim/Eli Lilly) Farxiga/Forxiga (dapagliflozin; AstraZeneca/ Xultophy/IDegLira (insulin degludec/ Bristol-Myers Squibb) [insulin/GLP-1 agonist]; Novo Nordisk) Invokana (; Johnson & Johnson) Ryzodeg (insulin degludec/insulin aspart [recombinant Jardiance (empagliflozin; Boehringer Ingelheim) human insulin]; Novo Nordisk)

5 KOLs Interviewed

T2DM: KOL Insight

KOLs from North America KOLs from EU

Jay S. Skyler, MD, MACP. Professor of Medicine, Professor Antonio Ceriello, MD. Head of the Research Paediatrics and Psychology and Deputy Director, Department on Diabetes and CVD, Institut Clinical Research and Academic Programmes, d'Investigacions Biomèdiques August Pi i Sunyer Diabetes Research Institute, University of Miami (IDIBAPS), Barcelona, Spain. Miller School of Medicine. Jens Holst, MD, PhD. Professor of medical physiology, Etie Moghissi, MD, FACP, FACE. Associate Clinical University of Copenhagen, Denmark. Professor of Medicine, UCLA David Geffen School of Medicine and Consultant in Diabetes, Endocrinology Bernard Charbonnel, MD. Professor of Endocrinology and Metabolism in Marina del Rey California, USA. and Metabolic Diseases, University of Nantes, France. John E. Anderson, MD. Past President, Medicine & Prof. Marc Y. Donath. Professor for Endocrinology, Head Science, American Diabetes Association (ADA), USA. of the Clinic for Endocrinology, Diabetes and Metabolism at the University Hospital of Basel, George Grunberger, MD, FACP, FACE. Chairman, Switzerland. Grunberger Diabetes Institute (GDI) in Bloomfield Hills, Michigan, USA. Prof. David Matthews, MA (Oxon), DPhil, BM, BCh, FRCP. Professor of Diabetes Medicine, University of Dr. Silvio Inzucchi MD. Professor of Medicine, Yale Oxford, and Medical Tutor & Dean at Harris Manchester University School of Medicine, New Haven, USA. College, Oxford, UK. Prof. Carol Wysham, MD. Research Professor, German KOL (Anonymous). Professor and head of Washington State University & Assistant Clinical Clinical Research in Diabetes at a leading university Professor of Medicine, University of Washington hospital in Germany. School of Medicine, USA.

6 Methodology

T2DM: KOL Insight

Secondary Research Detailed analysis of key marketed products and pipeline programmes, including key clinical data and trials

Primary Research Interviews with 12 of the world’s foremost KOLs

Analysis A balanced and independent qualitative review which clearly presents the factors impacting current and future product positioning and competitiveness 7 Methodology

T2DM: KOL Insight

Secondary Research: Analysis of key clinical data and ongoing trials enables the analyst to develop a robust understanding of each drug and develop research objectives which will answer important business questions about current and future product positioning and competitiveness.

8 Methodology

T2DM: KOL Insight

Primary Research: The KOLs are selected based on criteria which ensure we are getting feedback from the most influential leaders in the field of T2DM such as: • greater than 10 years experience in the field • greater than 30 percent of their time is spent treating patients • greater than 10 papers published in peer reviewed journals in the last 5 years • lead or principal investigator on clinical trials within last 5 years • has presented at major conferences at least 3 times in last 5 years • has recently served or currently serves as reviewer for peer reviewed scientific journals

9 Methodology

T2DM: KOL Insight

In-depth secondary research and (where appropriate) preparatory discussions with KOLs allows the analyst to develop the research objectives and discussion guide to ensure the research will gain valuable insights from KOLs and answer important business questions.

The analyst interviewing KOLs constantly monitors the market, is aware of the latest news/data and has a track record of gaining valuable insights from KOLs.

Analysis: Therapy Trends analysts review the interview transcripts and present an organised and balanced view of KOL opinions, adding clarity to complex issues.

10 Research Objectives

T2DM: KOL Insight

• Analysis of product attributes which confer preferred status

• Product perception by the medical community

• Clinical trials with greatest potential to impact prescribing trends

• Therapy attributes needed to become the treatment of choice

• The future role and potential impact of current and late-stage pipeline therapies

• Mapping the future evolution of the treatment landscape

11 Ongoing Benefits

T2DM: KOL Insight

PLUS – 3 quarterly updates on the treatment landscape:

FirstWord provides regular update bulletins in a disease area following the publication of a related Therapy Trends KOL Insight report. FirstWord analysts constantly monitor the market and at regular intervals obtain the reactions of KOLs to significant events, such as marketing approvals or the results of pivotal clinical trials. This continuous monitoring and frequent engagement with experts provides timely access to the strategic insights that support critical business decisions.

Buy online now

12